GenSight Biologics S.A.
SIGHT.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.15 | 0.02 | -0.05 |
| FCF Yield | -9.51% | -19.02% | -27.57% | -36.40% |
| EV / EBITDA | -6.65 | -6.21 | -5.77 | -3.44 |
| Quality | ||||
| ROIC | 157.63% | -413.67% | -154.68% | -1,019.05% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 113.24% |
| Cash Conversion Ratio | 0.35 | 0.69 | 1.26 | 0.59 |
| Growth | ||||
| Revenue 3-Year CAGR | -27.15% | -3.84% | 12.10% | 17.57% |
| Free Cash Flow Growth | 56.02% | 23.89% | 13.22% | 48.63% |
| Safety | ||||
| Net Debt / EBITDA | -2.79 | -2.25 | -2.14 | -1.42 |
| Interest Coverage | -3.13 | -13.54 | -15.89 | -6.32 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 1.87 | 0.10 | 1.82 | 263.47 |